MENU
Aim higher

THERIN

A therapeutic vaccine to eradicate pre-malignant HPV16 and HPV18 infection and prevent cancer

The consortium has 3 Goals: Commercial: Deliver proof-of-concept for elimination of pre-existing papillomavirus infection in non-human primates and a human candidate vaccine ready to enter clinical development. Science advance: The first therapeutic HPV vaccine in humans matching prophylactic vaccines in efficacy Social impact: Substantial prevention of virus-induced cancer on a global scale with the potential to lower healthcare expenses
Acronym: 
THERIN
Project ID: 
12 151
Ranking: 
6
Cut-off: 
8
Start date: 
03-07-2018
Project Duration: 
36months
Project costs: 
1 566 430.00€
Technological Area: 
Genetic Engineering
Market Area: 
Other therapeutic (including defibrillators)